Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro

References

• Zhou Y, Zheng T, Chen H, et al. Microbial intervention as a novel target in treatment of non-alcoholic fatty liver disease progression. Cell Physiol Biochem. 2018;51(5):2123–2135.
   PubMedGoogle Scholar
• Ma C, Yan K, Wang Z, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021;12(1):2187–2202.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, et al. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006;12(12):555–558.
   PubMed Web of Science ®Google Scholar
• Nair B, Nath LR. Inevitable role of TGF-β1 in progression of nonalcoholic fatty liver disease. J Recept Signal Transduct Res. 2020;40:195–200.
   PubMed Web of Science ®Google Scholar
• Tong J, D’Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes. 2014;63(2):407–409.
   PubMed Web of Science ®Google Scholar
• Zhang H, Chu Y, Zheng H, et al. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation. Aging (Albany NY). 2020;13:525–536.
   PubMedGoogle Scholar
• Li P, Tang Z, Wang L, et al. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice. Mol Med Rep. 2017;16(3):3421–3426.
   PubMed Web of Science ®Google Scholar
• Asadipooya K, Lankarani KB, Raj R, et al. RAGE is a potential cause of onset and progression of nonalcoholic fatty liver disease. Int J Endocrinol. 2019;2019:2151302.
   PubMed Web of Science ®Google Scholar
• Fernando DH, Forbes JM, Angus PW, et al. Development and progression of non-alcoholic fatty liver disease: the role of advanced glycation end products. Int J Mol Sci. 2019;20(20):10.3390/ijms20205037.
   Web of Science ®Google Scholar
• Pang Q, Sun Z, Shao C, et al. CML/RAGE signal bridges a common pathogenesis between atherosclerosis and non-alcoholic fatty liver. Front Med (Lausanne). 2020;7:583943.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Zhang J, Zhang X, et al. The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease. Free Radic Biol Med. 2018;115:412–420.
   PubMed Web of Science ®Google Scholar
• Jiang JX, Fish SR, Tomilov A, et al. Nonphagocytic activation of NOX2 is implicated in progressive nonalcoholic steatohepatitis during aging. Hepatology. 2020;72(4):1204–1218.
   PubMed Web of Science ®Google Scholar
• Sohn W, Jun DW, Lee KN, et al. Lactobacillus paracasei induces M2-dominant Kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(11):3340–3350.
   PubMed Web of Science ®Google Scholar
• Moreira GV, Azevedo FF, Ribeiro LM, et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem. 2018;62:143–154.
   PubMed Web of Science ®Google Scholar
• Long Q, Chen H, Yang W, et al. Delphinidin-3-sambubioside from Hibiscus sabdariffa. L attenuates hyperlipidemia in high fat diet-induced obese rats and oleic acid-induced steatosis in HepG2 cells. Bioengineered. 2021;12(1):3837–3849.
   PubMed Web of Science ®Google Scholar
• Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.
   PubMed Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393.
   PubMed Web of Science ®Google Scholar
• Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99–128.
   PubMed Web of Science ®Google Scholar
• Huang CJ, McAllister MJ, Slusher AL, et al. Obesity-related oxidative stress: the impact of physical activity and diet manipulation. Sports Med Open. 2015;1:32.
   PubMedGoogle Scholar
• Ogawa Y, Imajo K, Yoneda M, et al. [Pathophysiology of NAsh/NAFLD associated with high levels of serum triglycerides]. Nihon Rinsho. 2013;71(9):1623–1629.
   PubMedGoogle Scholar
• Liu D, Pang J, Shao W, et al. Hepatic fibroblast growth factor 21 is involved in mediating functions of liraglutide in mice with dietary challenge. Hepatology. 2021;74(4):2154–2169.
   PubMed Web of Science ®Google Scholar
• Wu YR, Shi XY, Ma CY, et al. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway. Cardiovasc Diabetol. 2019;18(1):146.
   PubMed Web of Science ®Google Scholar
• Tarafdar A, Pula G. The role of NADPH oxidases and oxidative stress in neurodegenerative disorders. Int J Mol Sci. 2018;19(12):10.3390/ijms19123824.
   PubMed Web of Science ®Google Scholar
• Sun J, Guo Y, Fan Y, et al. Decreased expression of IDH1 by chronic unpredictable stress suppresses proliferation and accelerates senescence of granulosa cells through ROS activated MAPK signaling pathways. Free Radic Biol Med. 2021;169:122–136.
   PubMed Web of Science ®Google Scholar
• Lee H, Park JR, Kim EJ, et al. Cigarette smoke-mediated oxidative stress induces apoptosis via the MAPKs/STAT1 pathway in mouse lung fibroblasts. Toxicol Lett. 2016;240:140–148.
   PubMed Web of Science ®Google Scholar
• Son Y, Kim S, Chung HT, et al. Reactive oxygen species in the activation of MAP kinases. Methods Enzymol. 2013;528:27–48.
   PubMed Web of Science ®Google Scholar
• Su LJ, Zhang JH, Gomez H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843.
   PubMed Web of Science ®Google Scholar
• Videla LA. Oxidative stress signaling underlying liver disease and hepatoprotective mechanisms. World J Hepatol. 2009;1(1):72–78.
   PubMedGoogle Scholar
• Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 2004;39(2):273–278.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sato A, Kishimoto Y, et al. Gallic acid inhibits lipid accumulation via AMPK pathway and suppresses apoptosis and macrophage-mediated inflammation in hepatocytes. Nutrients. 2020;12(5):10.3390/nu12051479.
   Web of Science ®Google Scholar
• Kocabayoglu P, Friedman SL. Cellular basis of hepatic fibrosis and its role in inflammation and cancer. Front Biosci. 2013;5:217–230.
   Google Scholar
• Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6(1):425–456.
   PubMedGoogle Scholar
• Sato M, Suzuki S, Senoo H. Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct. 2003;28(2):105–112.
   PubMed Web of Science ®Google Scholar
• Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 2008;88(1):125–172.
   PubMed Web of Science ®Google Scholar
• Atta H, El-Rehany M, Hammam O, et al. Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression. PLoS One. 2014;9(11):e112384.
   PubMed Web of Science ®Google Scholar